Biblio
Export 1237 results:
Author [ Title
Filters: First Letter Of Last Name is D [Clear All Filters]
“Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration.”, J Alzheimers Dis, vol. 56, no. 4, pp. 1505-1518, 2017.
, “Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline.”, J Alzheimers Dis, vol. 53, no. 1, pp. 85-93, 2016.
, “Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline.”, J Alzheimers Dis, vol. 53, no. 1, pp. 85-93, 2016.
, “Chinese Calligraphy Writing for Augmenting Attentional Control and Working Memory of Older Adults at Risk of Mild Cognitive Impairment: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 58, no. 3, pp. 735-746, 2017.
, “Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 633-43, 2016.
, “Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 633-43, 2016.
, “Characterizing Clinical and Neuropathological Traits of APOE Haplotypes in African Americans and Europeans.”, J Alzheimers Dis, vol. 78, no. 1, pp. 467-477, 2020.
, “Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.”, J Alzheimers Dis, vol. 50, no. 1, pp. 111-26, 2016.
, “Characterization of Amyloid-β Deposits in Bovine Brains.”, J Alzheimers Dis, vol. 51, no. 3, pp. 875-87, 2016.
, “Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.”, J Alzheimers Dis, vol. 51, no. 3, pp. 815-25, 2016.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
, “Change in Odor Identification Impairment is Associated with Improvement with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1525-1531, 2017.
, “Change in Fitness and the Relation to Change in Cognition and Neuropsychiatric Symptoms After Aerobic Exercise in Patients with Mild Alzheimer's Disease.”, J Alzheimers Dis, vol. 65, no. 1, pp. 137-145, 2018.
, “Cerebrovascular Disease and Neurodegeneration in Alzheimer's Disease with and without a Strong Family History: A Pilot Magnetic Resonance Imaging Study in Dominican Republic.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1519-1528, 2018.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1281-1297, 2021.
, “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
, “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
, “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
, “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
, “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
, “Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1107-1117, 2018.
,